abstract |
The present invention relates to a medicinal product administered to a subject in combination or sequentially to treat a Flaviviridae viral infection, eg, hepatitis C virus (HCV) infection, wherein the treatment comprises Administration of a compound effective to inhibit the function of the HCV NS5A protein, and an additional compound or combination of compounds having anti-HCV activity. |